Quanterix names yuri Fesko chief medical officer as diagnostics business expands. September 14, 2026 Dr. Yuri Fesko Quanterix Corporation has appointed Dr. Yuri Fesko chief medical officer, adding an experienced diagnostics executive as the company prepares for a broader market launch of its Lucent AD(R) Complete Alzheimer's disease test and advances regulatory work for its HD-X instrument. Fesko will provide medical and clinical leadership across the Nasdaq-listed precision biomarker company, working with its Diagnostics, Scientific, R&D, Regulatory and Commercial teams. He will be based at Quanterix's headquarters in Billerica, Massachusetts. The newly created role comes as Quanterix works to expand its diagnostics business and move more of its biomarker technologies into clinical applications. President and CEO Everett Cunningham said Fesko's background in clinical affairs and precision medicine will support both the commercialization of Lucent AD Complete and the company's planned IVD filing for HD-X. "As we prepare for the broader market launch of our Lucent AD Complete five biomarker test for Alzheimer's Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics," Cunningham said. Fesko most recently served as chief medical officer at Quest Diagnostics, where he oversaw Medical Affairs, Clinical Development, Analytics and Public Health. He also served as the medical lead supporting the company's Quality and Regulatory functions and provided senior medical leadership for pathology and dermatopathology. His experience spans the development and implementation of precision medicine strategies in oncology, metabolic disease, neurology and consumer health. He has worked with health systems, pharmaceutical and biotechnology companies, and physician organizations to integrate precision diagnostics into clinical practice and clinical trials. Fesko also brings experience supporting FDA submissions, clinical development programs, companion diagnostic strategies and reimbursement planning. Those capabilities are relevant as Quanterix works to translate its biomarker research technologies into regulated diagnostic products and expand their use in clinical settings. One immediate priority is Lucent AD Complete, Quanterix's five-biomarker blood test for Alzheimer's disease. The company is preparing for a broader market launch of the test while simultaneously advancing the IVD regulatory filing for its HD-X instrument, making medical, regulatory and commercialization coordination a central part of Fesko's mandate. Cunningham said Fesko's ability to work across medicine, diagnostics, analytics and business strategy will support the company's efforts to build its Diagnostics business and broaden the clinical applications of its technology. Quanterix develops precision biomarker technologies designed to detect and quantify biological markers at very low concentrations. Its Simoa(R) platform provides high-sensitivity biomarker measurement in blood and other fluids, supporting applications across disease research, diagnostics and drug development. The company's technology portfolio has also expanded through its acquisition of Akoya Biosciences. Quanterix Spatial solutions provide high-plex quantitative protein analysis in tissue at single-cell resolution, adding spatial biology capabilities alongside its existing fluid biomarker technologies. Quanterix also operates Accelerator Laboratory services, providing researchers with additional capabilities for moving biomarker discoveries toward diagnostic applications. Together, those businesses give the company a platform spanning biomarker measurement, spatial analysis and laboratory services as it increases its focus on precision diagnostics. Fesko earned both his bachelor's degree and Doctor of Medicine from Case Western Reserve University and completed a fellowship at University Hospitals of Cleveland. He is board-certified in internal medicine, hematology and medical oncology. His appointment adds senior clinical leadership at a point when Quanterix is managing both product commercialization and regulatory execution. As the company expands beyond research applications, Fesko will help coordinate the medical evidence, regulatory strategy and clinical adoption required to move its biomarker technologies more broadly into diagnostic workflows.

Bruker Corporation executive is named finance chief at Quanterix. New hire also worked at PAREXEL, Dell, and Harvard Business Publishing. August 21, 2026 Managing Editor, Rodman Media Quanterix Corporation has appointed Jason Faessler as chief financial officer. His extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry position him to play a pivotal role in executing Quanterix's future growth plans, company executives claim. "We are thrilled to welcome Jason to the Quanterix leadership team," Quanterix CEO Everett Cunningham said. "His extensive track record within life science organizations makes him the ideal leader to support our ambitious growth objectives. Jason's expertise in strategic financial and capital planning, operational excellence, and commercial support will be instrumental in advancing our mission." Faessler joins Quanterix from Bruker Corporation, where he was senior vice president, leading global FP&A and the Americas Finance organization. His responsibilities have included strategic planning, operational finance, and capital decision-making. Before Bruker, Faessler held senior finance leadership positions at PAREXEL, where he led its Early- and Late-Phase Clinical divisions, driving growth and profitability across both businesses. Jason also held senior financial management roles at EMC (now Dell) and Harvard Business Publishing. "I am both excited and honored to join Quanterix at this pivotal moment in its journey," Faessler stated. "The company is positioned for growth with two leading scientific instrument platforms and an emerging diagnostics capability. Quanterix's technology is enabling earlier disease detection and deeper insights into both research and clinical settings, helping to advance science and improve patient outcomes. I look forward to partnering with Everett and the leadership team to drive sustained value creation for our shareholders by capturing these opportunities." Quanterix provides ultra-sensitive biomarker detection solutions that enable breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa technology delivers sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,500 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,450 installed instruments. Together, the combined company offers an integrated platform that connects biology across blood and tissue - advancing precision medicine from discovery to diagnostics.

Quanterix cut its 2026 revenue guidance to $142 million–$148 million from $169 million–$174 million after second-quarter revenue of $32.9 million missed guidance by $3 million. The company cited broad market weakness and commercial execution challenges. Pro forma revenue declined 23% year over year, with weakness across key businesses and regions. Simoa revenue fell in the low teens, whilst Spatial revenue also declined. Academic and government demand remained particularly weak. The company completed its Akoya integration and achieved $85 million in annualised savings, lifting non-GAAP gross margin to 47.9%. Quanterix pushed its cash-flow breakeven target to 2027 from the end of 2026. It expects to end 2026 with approximately $80 million in cash and no debt.